Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

PolandBack to Poland

Clinical trials in Gliwice – page 9

164 clinical trials in Gliwice, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Gliwice at a glance
164
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

164 trials in Gliwice

Open in trial search

Squamous cell carcinoma of head and neck

Not recruiting

Study of INBRX-106 and Pembrolizumab for First-Line Treatment in Patients with Recurrent or Metastatic Head and Neck Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Inhibrx Biosciences Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Chronic lymphocytic leukaemia

Not recruiting

Study on the Effectiveness of Venetoclax and Rituximab for Patients with Untreated Chronic Lymphocytic Leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Polish Adult Leukemia Group

Diffuse large B-cell lymphoma+7

Not recruiting

Study on the Effectiveness and Safety of Cytarabine, Tafasitamab, and Lenalidomide for Patients with Relapsed Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Instytut Hematologii I Transfuzjologii

Squamous cell carcinoma of the oral cavity+9

Not recruiting

Study of low-dose radiation therapy combined with paclitaxel and carboplatin in patients with advanced throat and larynx cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Medullary thyroid cancer

Not recruiting

Comparison of two doses of cabozantinib (60 mg vs 140 mg) in patients with progressive metastatic medullary thyroid cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Endocrine ophthalmopathy

Not recruiting

Study on Batoclimab for Treating Patients with Active Thyroid Eye Disease

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Squamous cell carcinoma of head and neck

Not recruiting

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab with pembrolizumab compared to pembrolizumab alone in patients with head and neck cancer who have not received previous treatment for advanced disease

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Genmab A/S

Squamous cell carcinoma of head and neck

Not recruiting

Study of petosemtamab compared to standard therapy in previously treated patients with metastatic or recurrent head and neck cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Genmab A/S

Polycythaemia vera+10

Not recruiting

Study on Long-Term Safety of Ruxolitinib, Panobinostat, and Siremadlin for Patients Continuing Treatment from Previous Studies

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Panobinostat
  • Sponsor:Novartis Pharma Services AG

Hodgkin's disease+1

Not recruiting

Study of Pembrolizumab with Hyaluronidase for Patients with Relapsed or Refractory Hodgkin Lymphoma or Primary Mediastinal Large B-cell Lymphoma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Poland

The busiest research cities in the country

All 239 cities in Poland

Clinical research in Gliwice

What the registry says about research in the country

01 Hematologic Oncology

Innovative trials focusing on chronic lymphocytic leukemia and various lymphomas, testing novel combination therapies and personalized treatment approaches.

  • B-cell lymphomas and leukemias
  • CAR T-cell therapy
  • Targeted therapies

Research includes assessment of venetoclax combinations and novel immunotherapy approaches for blood cancers.

02 Solid Tumors

Comprehensive studies examining treatments for advanced solid tumors, including breast, lung, and colorectal cancers.

  • Immunotherapy combinations
  • Targeted molecular therapies
  • Novel drug combinations

Investigations focus on improving survival outcomes through innovative treatment strategies.

03 Head and Neck Cancers

Clinical trials evaluating new approaches for head and neck squamous cell carcinoma and throat cancers using radiochemotherapy and immunotherapy.

  • Low-dose radiation therapy
  • Combination treatments
  • Novel immunotherapy agents

Studies aim to enhance treatment efficacy while minimizing side effects.

Back to PolandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.